Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

TB-500 Scar Healing Mechanism: Research vs Marketing Comparison

'Reduces scar tissue formation' Supported. 30–50% reduction in fibrotic markers in controlled studies (Journal of Cellular Physiology, 2018) Inhibits TGF-β1-driven myofibroblast differentiation; upregulates MMP-2/MMP-9 for collagen remodeling Valid claim when

This comparison does not assign a generated winner or score.

  • 'Reduces scar tissue formation'
  • Supported. 30–50% reduction in fibrotic markers in controlled studies (Journal of Cellular Physiology, 2018)
  • Inhibits TGF-β1-driven myofibroblast differentiation; upregulates MMP-2/MMP-9 for collagen remodeling
  • Valid claim when applied during proliferative phase (days 3–14 post-injury); negligible effect outside this window
  • 'Reverses existing scars'
  • Not supported. No peer-reviewed evidence of mature scar reversal in humans
  • No known mechanism for breaking down cross-linked collagen in mature (>6 month) scars
  • Misleading. TB-500 affects scar formation during active healing, not established fibrotic tissue
  • 'Promotes angiogenesis'
  • Supported. 2.8× capillary density increase in preclinical wound models (Am J Pathology, 2019)
  • Enhances endothelial cell migration via actin dynamics; upregulates VEGF receptor expression
  • Valid mechanism. Increased vascularization improves oxygen/nutrient delivery during repair
  • 'Accelerates wound closure'
  • Supported with caveats. Faster closure in partial-thickness wounds; no difference in full-thickness wounds (Wound Repair Regen, 2016)
  • Enhances keratinocyte migration for re-epithelialization; minimal effect on deep dermal/fascial closure rates
  • Accurate for superficial wounds; exaggerated for deep tissue injuries that require fascial approximation
  • 'Eliminates scarring entirely'
  • Not supported. No wound healing occurs without some collagen deposition
  • Physiologically impossible. All wounds require extracellular matrix deposition for structural integrity
  • False claim. TB-500 improves scar quality (organization, width, pliability), does not prevent scar formation
More references

Related material

Comparison

Quickcomparison

Dose Range Thymosin Beta-4 2–5 mg TB-500 Frequency Twice weekly Administration Subcutaneous injection Cycle Length 8-12 weeks 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence L…

View details →